People: Zogenix Inc (ZGNX.O)

ZGNX.O on Consolidated Issue listed on NASDAQ Global Market

1.16USD
19 Dec 2014
Price Change (% chg)

-- (+0.00%)
Prev Close
$1.16
Open
$1.16
Day's High
$1.23
Day's Low
$1.15
Volume
7,791,007
Avg. Vol
1,930,703
52-wk High
$5.19
52-wk Low
$1.07

Search Stocks

Mast, Erle 

Brief Biography

Mr. Erle T. Mast is an Independent Director of Zogenix, Inc., since May 2008. Mr. Mast is a co-founder of and has served as Executive Vice President, Chief Financial Officer with Clovis Oncology, Inc. since May 2009. From July 2002 to May 2008, Mr. Mast served as Executive Vice President and Chief Financial Officer of Pharmion Corporation, until its acquisition by Celgene Corporation. From 2000 to 2002, after Elan Pharma International Ltd. acquired Dura Pharmaceuticals, Inc., Mr. Mast served as Chief Financial Officer for the Global Biopharmaceuticals business unit of Elan. From 1997 to 2000, Mr. Mast served as Vice President of Finance for Dura Pharmaceuticals. From 1984 to 1997, Mr. Mast held positions of increasing responsibility at Deloitte & Touche, LLP, serving most recently as Partner, where he provided accounting, auditing and business consulting services to companies in various industries, including the healthcare, pharmaceutical, biotech and manufacturing industries. Mr. Mast also serves on the board of directors of Somaxon Pharmaceuticals, Inc., Verus Pharmaceuticals, Inc. and Receptos, Inc. Mr. Mast received a degree in Business Administration from California State University, Bakersfield. Mr. Mast’s experience as a chief financial officer of various companies in the healthcare industry and in providing accounting, auditing and consulting services while at Deloitte & Touche, LLP, as well as his expertise in management, accounting, treasury, and finance functions, contributed to our board of directors’ conclusion that he should serve as a director of our company.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Cam Garner

--

Stephen Farr

1,402,760

Roger Hawley

1,834,500

Ann Rhoads

958,047

Bradley Galer

989,422

R. Scott Shively

989,635
As Of 30 Dec 2013
Search Stocks